Page last updated: 2024-09-03

hrp 102 and estriol

hrp 102 has been researched along with estriol in 2 studies

*Estriol: A hydroxylated metabolite of ESTRADIOL or ESTRONE that has a hydroxyl group at C3, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During PREGNANCY, a large amount of estriol is produced by the PLACENTA. Isomers with inversion of the hydroxyl group or groups are called epiestriol. [MeSH]

Compound Research Comparison

Studies (hrp 102)	Trials (hrp 102)	Recent Studies (post-2010) (hrp 102)	Studies (estriol)	Trials (estriol)	Recent Studies (post-2010) (estriol)
33	19	8	6,243	309	447

Protein Interaction Comparison

Protein	Taxonomy	hrp 102 (IC50)	estriol (IC50)
Estrogen receptor	Homo sapiens (human)		0.0017
Polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus (rabbit)		8.635

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cacciatore, B; Hasselblatt, R; Nieminen, MS; Paakkari, I; Tikkanen, MI; Toivonen, J; Ylikorkala, O	1
Strandberg, TE; Tikkanen, MJ; Ylikorkala, O	1

Trials

2 trial(s) available for hrp 102 and estriol

Article	Year
Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. American journal of obstetrics and gynecology, 2001, Volume: 184, Issue:5 Topics: Administration, Cutaneous; Administration, Oral; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Prospective Studies; Statistics, Nonparametric	2001
Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. The American journal of cardiology, 2003, Jul-15, Volume: 92, Issue:2 Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Norethindrone; Reference Values; Risk Factors	2003

Article

Year

Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women.

American journal of obstetrics and gynecology, 2001, Volume: 184, Issue:5

Topics: Administration, Cutaneous; Administration, Oral; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Prospective Studies; Statistics, Nonparametric

2001

Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women.

The American journal of cardiology, 2003, Jul-15, Volume: 92, Issue:2

Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Contraceptives, Oral, Combined; Drug Combinations; Estradiol; Estriol; Estrogen Replacement Therapy; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Norethindrone; Reference Values; Risk Factors

2003